Tailored cancer drug curbs melanoma recurrence in trial
Employees train to be cell therapy specialists at Gilead unit Kite’s manufacturing facility in Frederick Maryland, US, March 14, 2024. — Reuters US drugmakers Merck and Moderna said on Wednesday an experimental melanoma drug that delivers treatment tailored to a patient’s specific tumor prevented the cancer from returning in a large clinical trial. Called “intismeran…
